Remove 2029 Remove Patients Remove Pharma Remove Physicians
article thumbnail

Our abysmal health care system

World of DTC Marketing

The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. Patients and doctors are tired, and insurance companies are raising rates after two years of making a surplus because nobody went to the doctor during the pandemic.

Insurance 263
article thumbnail

Making Sense of the Latest Changes to the Market Access Landscape

PM360

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

article thumbnail

Price point is a key factor for wider market adoption of Amgen’s Amjevita in the US

Pharmaceutical Technology

Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 billion in 2022.